UNKL: A Potential Drug Target Or Biomarker (G64718)

Target Name: UNKL

NCBI ID: G64718

UNKL

UNKL: A Potential Drug Target Or Biomarker

UNKL (ZC3HDC5L), also known as UNKL-1, is a protein that is expressed in various tissues throughout the body. It is a key regulator of cell division and has been implicated in the development and progression of various diseases, including cancer. In In recent years, researchers have been interested in studying UNKL as a potential drug target or biomarker due to its unique biology and its potential to modulate cellular processes that are associated with human disease.

The UNKL gene was identified in the late 1990s and has since been shown to encode a protein that is involved in the regulation of cell division, specifically in the G1/S transition of cell division. The G1/S transition is a critical step in the cell cycle where the cell prepares for cell division by producing more copies of its genetic material. The UNKL protein plays a key role in regulating the G1/S transition by interacting with the transcription factor p21, which is responsible for activating the cell division cycle.

Studies have shown that UNKL is highly expressed in various tissues and types of cancer, including breast cancer, lung cancer, and colon cancer. Additionally, UNKL has been shown to be involved in the regulation of cell apoptosis, which is a natural mechanism for cell death that helps prevent the formation of cancer cells.

As a potential drug target, UNKL has been studied for its ability to modulate cellular processes that are associated with human disease. One of the main targets of UNKL is the regulation of cell division. Researchers have shown that UNKL can inhibit the activity of the transcription factor p21, which is responsible for activating the cell division cycle, and can also inhibit the production of cyclin D1, which is a critical component of the cell division cycle.

In addition to its ability to modulate cell division, UNKL has also been shown to play a role in the regulation of cell apoptosis. Studies have shown that UNKL can inhibit the production of pro-apoptotic proteins, such as Bax, and can also enhance the of anti-apoptotic proteins, such as Bcl-2. These proteins are involved in the production of regulation of cell death and have been implicated in the development and progression of various diseases, including cancer.

As a potential biomarker, UNKL has been shown to be involved in the regulation of cell division and cell apoptosis, which are important processes that are associated with human disease. This suggests that UNKL may be a useful biomarker for the diagnosis and treatment of various diseases. , including cancer.

In conclusion, UNKL is a protein that is involved in the regulation of cell division and cell apoptosis. Its unique biology and its potential to modulate cellular processes that are associated with human disease make it an attractive target for drug development and research into the underlying mechanisms of various diseases. Further studies are needed to fully understand the role of UNKL in cell biology and its potential as a drug target or biomarker.

Protein Name: Unk Like Zinc Finger

Functions: May participate in a protein complex showing an E3 ligase activity regulated by RAC1. Ubiquitination is directed towards itself and possibly other substrates, such as SMARCD2/BAF60b. Intrinsic E3 ligase activity has not been proven

The "UNKL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UNKL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets